INVO Fertility (IVF) Stock Price

INVO Fertility Price

NYSE·CLOSED
0.73
​
Market closed

Over the last 17 years INVO Fertility grew revenue by 35.7% annually, reaching 6.84 M USD. For INVO Fertility, the net margin of -340.9% is down versus -160.0% a few years ago.

INVO Fertility stock price

Access this data via the Eulerpool API

INVO Fertility business model & stock analysis

INVO Bioscience Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Lakewood Ranch, Florida and currently employs 15 full-time employees. The company went IPO on 2008-11-11. INVO Bioscience, Inc. is a healthcare services fertility company. The firm is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Company’s flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. The company operates three INVO Centers in North America.

Frequently asked questions about INVO Fertility

5 analysts currently rate the INVO Fertility stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect INVO Fertility to generate revenue of 10.42 M USD and earnings per share of -116.15 USD.

Converted at the current exchange rate, the INVO Fertility share trades at 0.65 EUR (0.73 USD).

The expected revenue of INVO Fertility is 10.42 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of INVO Fertility is -55.45 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of INVO Fertility is currently -0.01. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the INVO Fertility stock.

The price-to-sales ratio (P/S) of INVO Fertility is currently 0.03. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the INVO Fertility stock.

The Eulerpool Quality Score for INVO Fertility is 4/10.

The ISIN of INVO Fertility is US44984F8077. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of INVO Fertility is IVF. The ticker symbol is used to trade INVO Fertility shares on the stock exchange.

Fair ValueTerminal
0.61 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
456,083.33 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Nov 11, 2008
ISIN
US44984F8077
Cusip
44984F401
Market capitalization
1.74 M USDMicro Cap
52-Week Range
PEG
-0.00
P/E ratio
P/Ee 2026
-0.01
P/Ee 2027
-0.02
P/Ee 2028
-0.03
P/Ee 2029
-0.00
P/Ee 2030
-0.00
P/S
P/Se
0.03
EV/EBIT
—
P/B Ratio
0.24
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-219.54 %
Last updated Oct 12, 2026, 11:01 AM

INVO Fertility Peer Group